3
Total investments
2
Early stage
1
Mid stage
0
Late stage
3y
Years active
Portfolio
3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Nov 2025
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Our leadership team has made pivotal contributions to 13 FDA approvals (including recent MDD approval), $3.5B in M&A, and significant public company value creation.
As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.
Investor
Oct 2024
SE3 builds next-generation spatial AI for unmanned systems. SE3’s core technology combines advanced sensor fusion with semantic understanding to create a real-time 3D common operating picture. This foundation enables precise geolocation, target-grade coordinate generation for sensor-to-shooter chains, GNSS-denied swarming, and intuitive language-based interaction with complex spatial data. Advancing defence through spatial intelligence, SE3 strengthens Europe’s technological sovereignty.
Experience · 4 entries
All (4)
Investments (3)
2025
Investor
Nov 2025
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Our leadership team has made pivotal contributions to 13 FDA approvals (including recent MDD approval), $3.5B in M&A, and significant public company value creation.
As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.
2024
Investor
Oct 2024
SE3 builds next-generation spatial AI for unmanned systems. SE3’s core technology combines advanced sensor fusion with semantic understanding to create a real-time 3D common operating picture. This foundation enables precise geolocation, target-grade coordinate generation for sensor-to-shooter chains, GNSS-denied swarming, and intuitive language-based interaction with complex spatial data. Advancing defence through spatial intelligence, SE3 strengthens Europe’s technological sovereignty.
2023
Investor
Feb 2023
BVNK accelerates global money movement using stablecoins.
We make it easy for businesses to integrate stablecoins into their payments stack.
Note: BVNK will never ask a candidate to pay a verification fee.
2021
Senior Associate - Asset Management Assurance
Jan 2021
Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services*. Operating in over 100 countries and territories around the world, we draw on the expertise of more than 50,000 professionals – 33,000+ in Mazars’ integrated partnership and 17,000+ via the Mazars North America Alliance – to assist clients of all sizes at every stage in their development.
*Where permitted under applicable country laws
Investment activity
2023–2025 · 3 investments
Recent (last 2 years)Earlier
